These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28798269)

  • 21. The metabolic response using 18F-fluorodeoxyglucose-positron emission tomography/computed tomography and the change in the carcinoembryonic antigen level for predicting response to pre-operative chemoradiotherapy in patients with rectal cancer.
    Yoon MS; Ahn SJ; Nah BS; Chung WK; Song JY; Jeong JU; Nam TK
    Radiother Oncol; 2011 Jan; 98(1):134-8. PubMed ID: 21040991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?
    Staib L; Schirrmeister H; Reske SN; Beger HG
    Am J Surg; 2000 Jul; 180(1):1-5. PubMed ID: 11036130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
    Metser U; You J; McSweeney S; Freeman M; Hendler A
    AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
    Chen SW; Chen YK
    World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18F-FDG PET/CT superior to serum CEA in detection of colorectal cancer and its recurrence.
    Makis W; Kurzencwyg D; Hickeson M
    Clin Imaging; 2013; 37(6):1094-7. PubMed ID: 23993799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of Ki-67 proliferation index and 18-fluorodeoxyglucose uptake in colorectal incidental lesions detected by positron emission tomography-computed tomography.
    Güreşci S; Özmen Ö; Uzman M; Şimşek G; Tatci E; Gökçek A; Yeniova AÖ
    Turk J Med Sci; 2016 Jun; 46(4):1182-7. PubMed ID: 27513423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET).
    Flamen P; Hoekstra OS; Homans F; Van Cutsem E; Maes A; Stroobants S; Peeters M; Penninckx F; Filez L; Bleichrodt RP; Mortelmans L
    Eur J Cancer; 2001 May; 37(7):862-9. PubMed ID: 11313174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic value of (18)F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA.
    Gade M; Kubik M; Fisker RV; Thorlacius-Ussing O; Petersen LJ
    Cancer Imaging; 2015 Aug; 15(1):11. PubMed ID: 26263901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer.
    Hung GU; Shiau YC; Tsai SC; Chao TH; Ho YJ; Kao CH
    Anticancer Res; 2001; 21(2B):1375-8. PubMed ID: 11396217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [¹⁸F-FDG PET/CT. Its correlation with carcinoembryonic antigen in patients with colorectal carcinoma].
    Granados Rangel O; Estrada G; Altamirano J
    Gac Med Mex; 2014; 150(6):509-17. PubMed ID: 25375281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [F-18 fluorodeoxyglucose positron emission tomography in colorectal carcinoma].
    Jörg L; Langsteger W
    Wien Med Wochenschr; 2002; 152(11-12):276-9. PubMed ID: 12138655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated carcinoembryonic antigen and sarcoidosis masquerading as metastatic colon cancer.
    Gallagher DJ; Libby DM; Kemeny N
    Clin Colorectal Cancer; 2009 Jul; 8(3):172-4. PubMed ID: 19632934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer.
    Valk PE; Abella-Columna E; Haseman MK; Pounds TR; Tesar RD; Myers RW; Greiss HB; Hofer GA
    Arch Surg; 1999 May; 134(5):503-11; discussion 511-3. PubMed ID: 10323422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Multimodal imaging of breast cancer recurrence : Prospective intraindividual comparison of
    Avanesov M; Derlin T
    Radiologe; 2017 Jan; 57(1):1-3. PubMed ID: 27757490
    [No Abstract]   [Full Text] [Related]  

  • 38. FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA.
    Sarikaya I; Bloomston M; Povoski SP; Zhang J; Hall NC; Knopp MV; Martin EW
    World J Surg Oncol; 2007 Jun; 5():64. PubMed ID: 17555577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
    Laurens ST; Oyen WJ
    PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
    Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
    Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.